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UNRELATED DONOR CORD BLOOD TRANSPLANTATION FOR CHILDREN
WITH SEVERE SICKLE CELL DISEASE: RESULTS OF A PHASE II STUDY
FROM THE BLOOD AND MARROW TRANSPLANT CLINICAL TRIALS NET-
WORK
Kamani, N.R.1, Walters, M.2, Carter, S.3, Brochstein, J.A.4, Eapen, M.5,
Levine, J.E.6, Logan, B.5, Panepinto, J.5, Parikh, S.7, Pulsipher, M.8,
Schultz, K.R.9, Shenoy, S.10 1Children’s National Medical Center, Wash-
ington, DC; 2Children’s Hospital of Oakland, Oakland, CA; 3The
EMMES Corporation, Rockville, MD; 4Steven and Alexandra Cohen
Children’s Medical Center of New York, New Hyde Park, NY; 5Medical
College of Wisconsin, Milwaukee, WI; 6University of Michigan, Ann Ar-
bor, MI; 7Duke University, Durham, NC; 8University of Utah School of
Medicine, Salt Lake City, UT; 9BC Children’s Hospital, Vancouver, BC,
Canada; 10Washington University in St. Louis, St. Louis, MO
Most children with sickle cell disease (SCD) who might otherwise
be considered for curative hematopoietic cell transplantation (HCT)
lack a healthy matched related donor. Barriers to alternative donor
HCT for SCD include graft rejection, graft-versus-host disea-
se(GVHD) and regimen-related toxicities. To address these prob-
lems, we initiated a phase II trial of unrelated bone marrow or
cord blood transplantation (CBT) using a novel, alemtuzumab-
based, reduced intensity conditioning (RIC) regimen in children
with severe SCD. Here we report the results for the 8 children
who received unrelated CBT on this study. Patients were prepared
for HCT following alemtuzumab(10, 15 and 20 mg on day -21,
-20 and -19 respectively), fludarabine(30 mg/m2 day -8 to -4) and
melphalan(140 mg/m2 day -3). Cyclosporine or tacrolimus and my-
cophenolate were administered for GVHD prophylaxis. Donor/re-
cipient HLA match status was 5/6 in all patients based on low/
intermediate resolution molecular typing at HLA -A, -B, and high
resolution typing at -DRB1. Median recipient age was 13.7 years
(range 7.4 to 16.2 years). The median pre-cryopreservation total nu-
cleated cell dose was 6.4x107/kg (range 3.1 to 7.6) and the median
post-thaw infused CD34 cell dose was 1.5x105/kg (range 0.2 to
2.3). The conditioning regimen demonstrated a favorable safety pro-
file. All patients achieved an absolute neutrophil count.500/mm3 by
day 33 (median 22 days). Six of eight patients had a platelet recovery
to. 50,000/mm3 by day 100. Five patients had autologous hemato-
poietic recovery and three patients had sustained full donor engraft-
ment. Two of 3 engrafted patients developed grade II acute GVHD.
Of these, one developed extensive chronic GVHD that was fatal 14
months post-transplant. With a median follow up of 1.8 years (range
1 – 2.6), 7 patients are alive with a 1-year survival of 100% and 2 are
alive without graft failure or disease recurrence. Total nucleated or
CD 34+ cell dose, HLA mismatch or ABO mismatch were not cor-
related with graft rejection in this small series.
Conclusion: This RIC regimen was associated with a high rate of
graft rejection after unrelated CBT. The CBT arm has been closed,
but the trial remains open to enrollment for eligible patients with 8/8
HLA allele matched unrelated bone marrow donors. Novel ap-
proaches aimed at reducing graft rejection while minimizing toxicity
will be needed before RIC unrelated donorCBT can be widely adop-
ted for transplanting children with severe SCD.328
NiCORD EXPANDED HEMATOPOIETIC PROGENITOR CELLS (HPC) ARE
CAPABLE OF PROLONGED MYELOID AND LYMPHOID ENGRAFTMENT
FOLLOWING MYELOABLATIVE DUAL UMBILICAL CORD BLOOD (UCB)
TRANSPLANTATION
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Human transplantation of expanded HPCs resulting in durable,
robust donor myeloid and T-cell engraftment has yet to be reported.
We report here preliminary results of a pilot study of myeloablative
dual UCB transplantation where one UCB unit is expanded ex vivo
using the NiCord technology. The NiCord UCB graft consists of
an expanded AC133+ and a re-frozen unexpanded AC133- fraction.HPCs were expanded for 21 days in media containing hematopoietic
cytokines supplemented with nicotinamide (NAM), a vitamin B3 de-
rivative that delays differentiation and improves engraftment effi-
ciency of human HPCs. Patients were conditioned with total body
irradiation (1350cGy) and fludarabine 160mg/m2. Graft versus
host disease (GVHD) prophylaxis consisted of tacrolimus andmyco-
phenolate mofetil. Four patients (median age 46; range 41-61) with
AML (n 5 2) or MDS (n 5 2) received a NiCord-containing dual
UCB graft. The unmanipulated unit was HLA 4/6 (n 5 3) or 5/6
(n 5 1) matched with the patient and contained a median cryopre-
served TNC dose of 3 x 107/kg. The expanded unit was 4/6 matched
(n5 2) or 5/6 HLA-matched (n5 2) with the patient and contained
a median cryopreserved TNC dose of 2.3 x 107/kg. After expansion
of the AC133+ cell fraction, theTNCandCD34+ cell dose increased
a median 455 fold (range 321-577 fold) and 75 fold (range 46-100
fold), respectively. Patients received the NiCord unit that contained
a median TNC and CD34+ cell dose of 3.1 x 107/kg (range 1.8-4.3)
and 4.6 x 106/kg, respectively. The transplanted negative fraction
contained a median of 1.8 x 105 (range 0.8-2.8) CD3+ T-cells/kg.
All patients are durably engrafted, with a median time to
ANC.500 of 13 days (range 11-18) and platelets .20,000 of 32
days (range 30-36). Peripheral blood CD3+ and CD15+ cell chime-
rism from the 4 patients at the time of last follow-up are reported.
Patient 1, day +280; CD3 (NiCord-2%, unmanipulated-80%,
host-18%), CD15 (NiCord-64%, unmanipulated-36%). Patient 2,
day +180; CD3 (NiCord-100%), CD15 (NiCord-100%). Patient
3, day +60; CD3 (NiCord-93%, host-7%), CD15 (NiCord-98%,
host-2%) Patient 4, day +60; CD3 (unmanipulated-100%), CD15
(unmanipulated-100%). There were no infusion-related or unex-
pected adverse events and all patients are alive and well without
GVHD. These data demonstrate prompt and prolonged engraft-
ment of both myeloid and lymphoid cells derived from expanded
HPCs (NiCord) in 3 of 4 patients treated to date. Longer follow-
up is required to confirm durability.329
SPACE AND TOLERANCE ARE CRITICAL FOR ENGRAFTMENT OF HEMATO-
POIETIC ALLOGRAFTS IN RECIPIENTS CONDITIONED WITH TOTAL LYM-
PHOID IRRADIATION PLUS ATG
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Total lymphoid irradiation (TLI) is a unique non-myeloablative
conditioning regimen for allogeneic hematopoietic cell transplanta-
tion (HCT) that targets major lymph node groups, but spares areas
of bone marrow (BM). Such radiation plus anti-thymocyte globulin
(ATG) create a tolerogenic host environment, permitting donor en-
graftment while ameliorating GVHD. Here we studied the role of
‘tolerance induction’, immune- and spatial barriers that hematopoi-
etic stem cells (HSC) encounter in mice conditioned with TLI/
ATG. 17x240 cGy TLI+3xATG were more lymphoablative than le-
thal total body irradiation (TBI). Lymphoablation was accompanied
by a proportional (but not absolute) increase of T regulatory cells
(Tregs) post-TLI/ATG. Long-term HSC (cKit+Sca+Lin-CD34-
Flt3-Slam+) were normal in number in unexposed legs, increased
in spleen and liver, but eradicated in irradiated spines. To segregate
the effects of host barriers from facilitating donor cells or graft vs
host reactivity, purified HSC (cKit+Thy1.1loSca-1+Lin-) were
used as grafts. Bioluminescence imaging revealed that across differ-
ent genetic barriers, overall, donor cell expansion was slower in TLI/
ATG vs TBI-treated hosts, and donor hematopoiesis was restricted
to exposed spine areas. FACS analyses confirmed that 4 wks after
TLI/ATG + congenic or minor antigen mismatched HCT hemato-
poiesis in the BM of shielded legs was fully host-derived, and only
areas within the TLI-field contained mixed donor/host chimerism,
including the HSC. The degree of donor chimerism differed be-
tween blood lineages, but remained stable over time. All T cell pro-
genitor stages in the thymus had similar proportions of donor
contribution, implying that the degree of donor chimerism is deter-
mined by the available space in the BM early post-TLI. The impor-
tance of tolerance-inducing host cells (Treg, NKT) was illustrated
using TLI/ATG-conditioned Rag2g-/- recipients (no NK, T, or B
cells), which, despite their lack of classical cellular immune barriers,
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clusion, both, vacating of HSC niche space, and the effects of host
regulatory cells, that are activated during the TLI procedure appear
critical to permit donor HSC engraftment post-TLI/ATG. The dy-
namics of engraftment after TLI/ATGare unique. Further studies to
define the exact roles of host Tregs and NKT cells in engraftment
after TLI/ATG and other conditioning modalities are underway.330
IMMUNE RECONSTITUTION AND CLINICAL OUTCOME AFTER HSCT
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Background: Hematopoietic stem cell transplantation (HSCT) is
the treatment of choice for severe combined immunodeficiency
(SCID). There remains debate on whether to pre-condition with
chemotherapy prior to infusion of stem cells.We aimed to determine
the long-term progress of classic SCID patients who had undergone
HSCT infusion at our centre, with respect to clinical outcome and
immune comparing outcome based on transplant at \3 or .3
months of age, and molecular diagnosis.
Methods: A retrospective case notes review of patients undergoing
a first HSCT infusion for classic SCID from 01/1995 to 02/2011,
surviving. 2 months. Patients with previous HSCT were excluded.
Parameters analyzed included clinical outcome, chimerism, lympho-
cyte subsets including recent thymic emigrants, specific antibody
levels and Ig replacement. Statistical analysis was performed using
c 2 (Fisher exact test) and nonparametric wilcoxon rank sum. A 2-
sided p value\ 0.05 was considered significant.
Results: Twenty seven of 100 patients with SCID treated fulfilled
the study criteria; 10 had ADA deficiency, 7 had T-B-NK+ pheno-
type, 8 had CgC/JAK3 SCID, and 2 had other forms of SCID. 12
were transplanted\ 3 months of age, median age at HSCT was 3
months (range 0-8 months). Twenty had infection at diagnosis, all
. 3 months. Eleven had MSD, 1 MMSD, 5 MFD, 3 MMFD, 6
MUD, 1MMUD.Twenty receivedGvHDprophylaxis. Median fol-
low up was 80 months (2-187). Seven developed grade II-IV GvHD,
3 grade III. Five were re-transplanted, 2 received boost infusion for
poor engraftment (1 CgC, 1 T-B-NK+), 3 received a conditioned
HSCT (3 T-B-NK+). TRMwas 11% (1 ADA, 2T-B-NK+). Neuro-
logical and autoimmune complications were more common in the
ADA and T-B-NK+ groups. Recent thymic emigrants were most
commonly present in the CgC/JAK3 and ADA groups, and absent
from the T-B-NK+ group. The ADA group had the most complete
donor chimerism including myeloid chimerism, T-B-NK+ SCID
only achieved donor T cell chimerism. Most ADA patients discon-
tinued IVIG, compared to none with T-B-NK+ SCID.
Conclusion: HSCT infusion is an effective treatment for SCID.
Best results are obtained if transplanted\ 3 months of age. Estab-
lishment of donor B cell chimerism may require additional therapies
to achieve engraftment within the stem cell niche in all but ADA
SCID.331
DECITABINE IN COMBINATION WITH DONOR LYMPHOCYTE INFUSION
AS SALVAGE THERAPY FOR RELAPSED AML POST-ALLOGENEIC STEM
CELL TRANSPLANTATION
Kritharis, A., Donahue, L.L., Keyzner, A., Devoe, C., Bayer, R.L. Hofstra
University School of Medicine, North Shore LIJ Health System, Lake Suc-
cess, NY
Prognosis is extremely poor for AMLpatients who relapse after al-
logeneic stem cell transplantation. Donor Lymphocyte infusions
(DLI) can be used to salvage these patients with complete responserates reported to be 10-15% with an associated 40-60% chance of
developing clinically significant GVHD. The mechanism by which
DLI results in clinical responses is thought to be a T-cell mediated
process. Data suggest that DLI normalizes the T-cell receptor rep-
ertoire and expands the anti-leukemic cell population. Hypomethy-
lating agents, which appear to foster the graft versus leukemia
phenomenon, were combined with DLI in attempt to enhance the
graft versus leukemia effect.
We report ten AML patients who received Decitabine +/- Eto-
poside with incremental DLI as salvage after relapse from alloge-
neic stem cell transplantation during the years 2007-2010. These
patients were between the ages of 26- 73 years. Six patients had
de novo AML. Three patients were transformed from MDS, and
one from essential thrombocythemia. Eight patients had reduced
intensity conditioning regimens. Two patients received a fully ab-
lative preparative regimen. Average time to progression post trans-
plant was 17 months.
Patients received Decitabine at 20mg/m2 for 5 - 10 days, some in
combination with Etoposide for 3-5days for disease control. Patients
received 1-4 courses of treatment approximately every 28 days with
DLI between days 14-21. Two patients who progressed while receiv-
ing Decitabine/Etoposide received Clofarabine at 20-52mg/m2 for 5
days, with subsequent DLI. Cell dose ranged from 1.27 to 31.7
CD3+ cells / kg. Two patients received a mobilized DLI.
Six out of ten patients regained full chimerism. One patient who
relapsed with extra medullary disease never lost his graft. Seven out
of ten patients achieved a complete remission. Only one patient de-
veloped Grade 2 GVHD of the skin. Overall survival in these pa-
tients after relapse from allogeneic transplantation was 10.8
months.
The combination of Decitabine and DLI is a well tolerated outpa-
tient therapeutic option for patients with relapsed AML post alloge-
neic stem cell transplantation. The majority of patients regained full
chimerism and achieved complete remission with little or no
GVHD.332
IS THE USE OF 9/10 HLA UNRELATED DONORS STILL ACCEPTABLE IN
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR
HEMATOLOGICAL MALIGNANCIES? COMPARISON WITH TRANSPLANTS
FROM 10/10 HLA UNRELATED DONORS AND SIBLINGS
Michallet, M., Sobh, M., Morisset, S., Detrait, M., Labussiere, H.,
Tedone, N., Ducastelle, S., Barraco, F., Chelghoum, Y., Thomas, X.,
Nicolini, F.E. Centre Hospitalier Lyon Sud, Pierre Benite, France
To evaluate the outcome of allo-HSCT from 9/10 HLA mis-
matched unrelated donors compared to those from 10/10HLA iden-
tical unrelated donors and siblings; we retrospectively studied the
outcome of 213 patients who received allo-HSCT for different he-
matological malignancies, 121 (57%) from HLA identical siblings,
63 (29%) from 10/10 HLA identical unrelated donors and 29
(14%) from 9/10 HLA mismatched unrelated donors between
2006 and 2011 at our institution. The different patient characteris-
tics and figures will be provided in the future during the presentation.
After HSCT, engraftment was significantly lower in the 9/10 HLA
group (90%) than in the 10/10 HLA group (95%) than in the sibling
group (99%), (p5 0.03); the cumulative incidence of acute GVHD.
5 2 at 3 months was 32% (23-41), 20% (15-26) and 27% (23-32) re-
spectively; the cumulative incidence of extensive chronic GVHD at
one year was 21% (13-30), 9% (5-13) and 17% (14-21) for the 3
groups respectively. After a median follow-up of 8 months (0-54)
in the 9/10 HLA group, 10 months (0-60) in the 10/10 HLA group
and 18 months in the siblings group, the median OS was 10 months
(5-21), 18months (11-NR) and 60months (31-NR) respectively with
a 2-years probability of 19% (8-44), 43% (31-59) and 63% (54-74)
respectively. There was a higher but not significant relapse incidence
at one year in the 9/10 HLA group compared to other groups while
the TRM was significantly higher with a cumulative incidence at 1
year of 45% (35-55) vs. 33% (27-39) for 10/10 and 12%(9-15) for
siblings, (p\0.001). In multivariate analysis, OS was negatively af-
fected by unrelated donors [9/10 HR 5 5 (2.7-10), p 5 0.0001;
10/10 HR 5 2 (1.2-4), p 5 0.01], female donors [HR 5 2 (1.4-4),
p 5 0.03] and disease status\CR1 or\chronic phase 1 [HR 5 3
(1.4-6), p 5 0.003]; while the TRM was negatively affected by
